Vesugen is a peptide that people use off‑label; it has no FDA‑approved indication and all human applications rely on compounded formulations. Because no standard dosing or cycling regimen has emerged in the community, users typically follow individual protocols based on limited anecdotal reports. The primary limitation to keep in mind is that every human use is off‑label, meaning safety and efficacy are not established by regulatory review.
Data last updated
Measured on 3 of 6 axes
Evidence shape
Vesugen currently exists as an animal-only research peptide with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic research, providing no data on safety or efficacy in human subjects. Because there are zero registered trials and no completed human studies, the evidence base remains entirely theoretical and lacks the necessary foundation for clinical application.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column
How VESUGEN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
According to the sole source cited, clinicians use 200 mcg of VESUGEN taken sublingually each day, with no reported cycling or weight-based dosing.
Based on a single community report, users describe a 2 mg subcutaneous dose of VESUGEN, with no frequency or cycling details provided.